Spero Therapeutics (SPRO) Return on Capital Employed (2017 - 2025)
Historic Return on Capital Employed for Spero Therapeutics (SPRO) over the last 9 years, with Q3 2025 value amounting to 1.05%.
- Spero Therapeutics' Return on Capital Employed fell 10800.0% to 1.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.05%, marking a year-over-year decrease of 10800.0%. This contributed to the annual value of 0.75% for FY2024, which is 9700.0% down from last year.
- Latest data reveals that Spero Therapeutics reported Return on Capital Employed of 1.05% as of Q3 2025, which was down 10800.0% from 1.05% recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Return on Capital Employed registered a high of 0.24% during Q4 2023, and its lowest value of 2.0% during Q3 2022.
- Over the past 5 years, Spero Therapeutics' median Return on Capital Employed value was 0.63% (recorded in 2021), while the average stood at 0.6%.
- In the last 5 years, Spero Therapeutics' Return on Capital Employed surged by 19700bps in 2023 and then crashed by -13300bps in 2025.
- Quarter analysis of 5 years shows Spero Therapeutics' Return on Capital Employed stood at 0.63% in 2021, then increased by 10bps to 0.57% in 2022, then soared by 142bps to 0.24% in 2023, then crashed by -521bps to 0.99% in 2024, then fell by -6bps to 1.05% in 2025.
- Its Return on Capital Employed was 1.05% in Q3 2025, compared to 1.05% in Q2 2025 and 1.14% in Q1 2025.